Ventricular assist device related infections and solid organ transplantation

American Journal of Transplantation

Volumn 13, Issue SUPPL.4, 2013, Pages 348-354

  Koval, C E ^a   Rakita, R ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Bacterial infection; fungal infection; infectious complications; ventricular assist devices

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; RIFAMPICIN;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASPERGILLUS; BLOOD CULTURE; BLOODSTREAM INFECTION; CANDIDA; COMPUTER ASSISTED TOMOGRAPHY; CORYNEBACTERIUM; DEATH; DEVICE INFECTION; DISEASE SEVERITY; ENDOCARDITIS; ENTEROCOCCUS; HEART FAILURE; HEART VALVE PROSTHESIS; HISTOPATHOLOGY; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; LEUKOCYTE COUNT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; ORGAN TRANSPLANTATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEPSIS; SEPTIC SHOCK; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STAPHYLOCOCCUS AUREUS; VACUUM ASSISTED CLOSURE; VENTRICULAR ASSIST DEVICE;

ANTI-INFECTIVE AGENTS; HEART-ASSIST DEVICES; HUMANS; INFECTION; INFECTION CONTROL; ORGAN TRANSPLANTATION; RISK FACTORS;

EID: 84874928016     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12126     Document Type: Article

References (52)

1. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007; 357: 885-896.
2. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361: 2241-2251.
3. Lahpor J, Khaghani A, Hetzer R, et al. European results with a continuous-flow ventricular assist device for advanced heart-failure patients. Eur J Cardiothorac Surg 2010; 37: 357-361.
4. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345: 1435-1443.
5. Kirklin JK, Naftel DC, Kormos RL, et al. The Fourth INTERMACS Annual Report: 4,000 implants and counting. J Heart Lung Transplant 2012; 31: 117-126.
6. Bomholt T, Moser C, Sander K, et al. Driveline infections in patients supported with a HeartMate II: Incidence, aetiology and outcome. Scand Cardiovasc J 2011; 45: 273-278.
7. Gordon RJ, Quagliarello B, Lowy FD,. Ventricular assist device-related infections. Lancet Infect Dis 2006; 6: 426-437.
8. Califano S, Pagani FD, Malani PN,. Left ventricular assist device-associated infections. Infect Dis Clin North Am 2012; 26: 77-87.
9. Toba FA, Akashi H, Arrecubieta C, Lowy FD,. Role of biofilm in Staphylococcus aureus and Staphylococcus epidermidis ventricular assist device driveline infections. J Thorac Cardiovasc Surg 2011; 141: 1259-1264.
10. Pereda D, Conte JV,. Left ventricular assist device driveline infections. Cardiol Clin 2011; 29: 515-527.
11. Simon D, Fischer S, Grossman A, et al. Left ventricular assist device-related infection: Treatment and outcome. Clin Infect Dis 2005; 40: 1108-1115.
12. Monkowski DH, Axelrod P, Fekete T, Hollander T, Furukawa S, Samuel R,. Infections associated with ventricular assist devices: Epidemiology and effect on prognosis after transplantation. Transpl Infect Dis 2007; 9: 114-120.
13. Schaffer JM, Allen JG, Weiss ES, Arnaoutakis GJ, Patel ND, Russell SD, et al. Infectious complications after pulsatile-flow and continuous-flow left ventricular assist device implantation. J Heart Lung Transplant 2011; 30: 164-174.
14. Aslam S, Hernandez M, Thornby J, Zeluff B, Darouiche RO,. Risk factors and outcomes of fungal ventricular-assist device infections. Clin Infect Dis 2010; 50: 664-671.
15. Holman WL, Kormos RL, Naftel DC, et al. Predictors of death and transplant in patients with a mechanical circulatory support device: A multi-institutional study. J Heart Lung Transplant 2009; 28: 44-50.
16. Gordon SM, Schmitt SK, Jacobs M, et al. Nosocomial bloodstream infections in patients with implantable left ventricular assist devices. Ann Thorac Surg 2001; 72: 725-730.
17. Topkara VK, Kondareddy S, Malik F, et al. Infectious complications in patients with left ventricular assist device: Etiology and outcomes in the continuous-flow era. Ann Thorac Surg 2010; 90: 1270-1277.
18. Zierer A, Melby SJ, Voeller RK, et al. Late-onset driveline infections: The Achilles' heel of prolonged left ventricular assist device support. Ann Thorac Surg 2007; 84: 515-520.
19. Kimball PM, Flattery M, McDougan F, Kasirajan V,. Cellular immunity impaired among patients on left ventricular assist device for 6 months. Ann Thorac Surg 2008; 85: 1656-1661.
20. Yamani MH, Chuang HH, Ozduran V, et al. The impact of hypogammaglobulinemia on infection outcome in patients undergoing ventricular assist device implantation. J Heart Lung Transplant 2006; 25: 820-824.
21. Itescu S, John R,. Interactions between the recipient immune system and the left ventricular assist device surface: Immunological and clinical implications. Ann Thorac Surg 2003; 75 (6 Suppl): S58-65.
22. Ankersmit HJ, Tugulea S, Spanier T, et al. Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist device. Lancet 1999; 354: 550-555.
23. Sims DB, Uriel N, Gonzalez-Costello J, et al. Human immunodeficiency virus infection and left ventricular assist devices: A case series. J Heart Lung Transplant 2011; 30: 1060-1064.
24. Hannan MM, Husain S, Mattner F, et al. Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. J Heart Lung Transplant 2011; 30: 375-384.
25. Fischer SA, Trenholme GM, Costanzo MR, Piccione W,. Infectious complications in left ventricular assist device recipients. Clin Infect Dis 1997; 24: 18-23.
26. Myers TJ, McGee MG, Zeluff BJ, Radovancevic B, Frazier OH,. Frequency and significance of infections in patients receiving prolonged LVAD support. ASAIO Trans 1991; 37: M283-5.
27. Litzler PY, Manrique A, Etienne M, et al. Leukocyte SPECT/CT for detecting infection of left-ventricular-assist devices: Preliminary results. J Nucl Med 2010; 51: 1044-1048.
28. Chamogeorgakis T, Koval CE, Smedira NG, Starling RC, Gonzalez-Stawinski GV,. Outcomes associated with surgical management of infections related to the HeartMate II left ventricular assist device: Implications for destination therapy patients. J Heart Lung Transplant 2012; 31: 904-906.
29. Yuh DD, Albaugh M, Ullrich S, Conte JV,. Treatment of ventricular assist device driveline infection with vacuum-assisted closure system. Ann Thorac Surg 2005; 80: 1493-1495.
30. Sharma V, Deo SV, Stulak JM, et al. Driveline infections in left ventricular assist devices: Implications for destination therapy. Ann Thorac Surg 2012; 94: 1381-1386.
31. Shafii AE, Chamogeorgakis TP, Gonzalez-Stawinski G,. Omental flap transposition with intra-abdominal relocation for LVAD pump-pocket infection. J.Heart Lung Transplant 2011; 30 (12): 1421-1422.
32. Toda K, Yonemoto Y, Fujita T, Shimahara Y, Sato S, Nakatani T, et al. Risk analysis of bloodstream infection during long-term left ventricular assist device support. Ann Thorac Surg 2012.
33. Morgan JA, Park Y, Oz MC, Naka Y,. Device related infections while on left ventricular assist device support do not adversely impact bridging to transplant or posttransplant survival. ASAIO J 2003; 49: 748-750.
34. Scherer M, Sirat AS, Moritz A, Martens S,. Extracorporeal membrane oxygenation as perioperative right ventricular support in patients with biventricular failure undergoing left ventricular assist device implantation. Eur J Cardiothorac Surg 2011; 39: 939-944.
35. John R, Pagani FD, Naka Y, et al. Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: Impact of duration of left ventricular assist device support and other variables. J Thorac Cardiovasc Surg 2010; 140: 174-181.
36. Schulman AR, Martens TP, Russo MJ, et al. Effect of left ventricular assist device infection on post-transplant outcomes. J Heart Lung Transplant 2009; 28: 237-242.
37. Bagdasarian NG, Malani AN, Pagani FD, Malani PN,. Fungemia associated with left ventricular assist device support. J Card Surg 2009; 24: 763-765.
38. de Repentigny L, St-Germain G, Charest H, Kokta V, Vobecky S,. Fatal zygomycosis caused by Mucor indicus in a child with an implantable left ventricular assist device. Pediatr Infect Dis J 2008; 27: 365-369.
39. Eschertzhuber S, Velik-Salchner C, Hoermann C, Hoefer D, Lass-Florl C,. Caspofungin-resistant Aspergillus flavus after heart transplantation and mechanical circulatory support: A case report. Transpl Infect Dis 2008; 10: 190-192.
40. Edwards FH, Engelman RM, Houck P, Shahian DM, Bridges CR,; Society of Thoracic Surgeons. The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic prophylaxis in cardiac surgery. Part I: Duration. Ann Thorac Surg 2006; 81: 397-404.
41. Engelman R, Shahian D, Shemin R, et al. The Society of Thoracic Surgeons practice guideline series: Antibiotic prophylaxis in cardiac surgery. Part II: Antibiotic choice. Ann Thorac Surg 2007; 83: 1569-1576.
42. Walker PC, DePestel DD, Miles NA, Malani PN,. Surgical infection prophylaxis for left ventricular assist device implantation. J Card Surg 2011; 26: 440-443.
43. Acharya MN, Som R, Tsui S,. What is the optimum antibiotic prophylaxis in patients undergoing implantation of a left ventricular assist device? Interact Cardiovasc Thorac Surg 2012; 14: 209-214.
44. Hozayen SM, Soliman AM, Eckman PM,. Comparison of two ventricular assist device dressing change protocols. J Heart Lung Transplant 2012; 31: 108-109.
45. Sharma MS, Webber SA, Gandhi SK, et al. Pulsatile paracorporeal assist devices in children and adolescents with biventricular failure. ASAIO J 2005; 51: 490-494.
46. Sharma MS, Forbess JM, Guleserian KJ,. Ventricular assist device support in children and adolescents with heart failure: The Children's Medical Center of Dallas Experience. Artif Organs 2012; 36: 635-639.
47. Fraser CD, Jr, Jaquiss RD, Rosenthal DN, Humpl TFA,. Prospective trial of a pediatric ventricular assist device. 2012; 367: 532-541.
48. Strueber M, O'Driscoll G, Jansz P, et al. Multicenter evaluation of an intrapericardial left ventricular assist system. J Am Coll Cardiol 2011; 57: 1375-1382.
49. Wu L, Weng YG, Dong NG, et al. Outcomes of the HeartWare Ventricular Assist System support in 141 patients: A single-centre experience. Eur J Cardiothorac Surg 2012: 1-7.
50. Hernandez MD, Mansouri MD, Aslam S, Zeluff B, Darouiche RO,. Efficacy of combination of N-acetylcysteine, gentamicin, and amphotericin B for prevention of microbial colonization of ventricular assist devices. Infect Control Hosp Epidemiol 2009; 30: 190-192.
51. Slaughter MS, Myers TJ,. Transcutaneous energy transmission for mechanical circulatory support systems: History, current status, and future prospects. J Card Surg 2010; 25: 484-489.
52. Stein ML, Robbins R, Sabati AA, et al. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS)-defined morbidity and mortality associated with pediatric ventricular assist device support at a single US center. Circ Heart Fail 2010; 3: 682-688.